bpc 157 bitcoin BPC-157 BPC-157 Canada — Research-Grade BPC-157

This tiny but powerful angiogenic chemical compound has the potential to be effective in treating neurodegenerative disorders caused by disease or traumatic injury

OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship

Her father had died from a heart attack at 58

pylori negative patients (105)